FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092923321> ?p ?o ?g. }

• W2092923321 endingPage "1010" @default.
• W2092923321 startingPage "1001" @default.
• W2092923321 abstract "FLT3 is a member of the type III receptor tyrosine kinase (RTK) family. These receptors all contain an intrinsic tyrosine kinase domain that is critical to signaling. Aberrant expression of the FLT3 gene has been documented in both adult and childhood leukemias including AML, ALL and CML. In addition, 17–27% of pediatric and adult patients with AML have small internal tandem duplication mutations in FLT3. Patients expressing the mutant form of the receptor have been shown to have a decreased chance for cure. Our previous study, using a constitutively activated FLT3, demonstrated transformation of Ba/F3 cells and leukemic development in an animal model. Thus, there is accumulating evidence for a role for FLT3 in human leukemias. This has prompted us to search for inhibitors of FLT3 as a possible therapeutic approach in these patients. AG1296 is a compound of the tyrphostin class that is known to selectively inhibit the tyrosine kinase activity of the PDGF and KIT receptors. Since FLT3 is a close relative of KIT, we wanted to test the possible inhibitory activity of AG1296 on FLT3. In transfected Ba/F3 cells, AG1296 selectively and potently inhibited autophosphorylation of FL-stimulated wild-type and constitutively activated FLT3. Treatment by AG1296 abolished IL-3-independent proliferation of Ba/F3 cells expressing the constitutively activated FLT3 and thus, reversed the transformation mediated by activated FLT3. Inhibition of FLT3 activity by AG1296 in cells transformed by activated FLT3 resulted in apoptotic cell death, with no deleterious effect on their parental counterparts. Addition of IL-3 rescued the growth of cells expressing activated FLT3 in the presence of AG1296. This demonstrates that the inhibition is specific to the FLT3 pathway in that it leaves the kinases of the IL-3 pathway and other kinases further downstream involved in proliferation intact. Several proteins phosphorylated by the activated FLT3 signaling pathway, including STAT 5A, STAT 5B and CBL, were no longer phosphorylated when these cells were treated with AG1296. The activity against FLT3 suggests a potential therapeutic application for AG1296 or similar drugs in the treatment of leukemias involving deregulated FLT3 tyrosine kinase activity and as a tool for studying the biology of FLT3." @default.
• W2092923321 created "2016-06-24" @default.
• W2092923321 creator A5018989541 @default.
• W2092923321 creator A5020250954 @default.
• W2092923321 creator A5047214928 @default.
• W2092923321 creator A5047497411 @default.
• W2092923321 creator A5052789124 @default.
• W2092923321 date "2001-07-01" @default.
• W2092923321 modified "2023-10-12" @default.
• W2092923321 title "Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor" @default.
• W2092923321 cites W134922517 @default.
• W2092923321 cites W1486112083 @default.
• W2092923321 cites W1506423591 @default.
• W2092923321 cites W1510108058 @default.
• W2092923321 cites W1542395305 @default.
• W2092923321 cites W1547318123 @default.
• W2092923321 cites W1592402132 @default.
• W2092923321 cites W1608356737 @default.
• W2092923321 cites W1966112698 @default.
• W2092923321 cites W1968306285 @default.
• W2092923321 cites W1978469902 @default.
• W2092923321 cites W1981096579 @default.
• W2092923321 cites W1985349116 @default.
• W2092923321 cites W1985357637 @default.
• W2092923321 cites W1989512056 @default.
• W2092923321 cites W1996606746 @default.
• W2092923321 cites W1998749892 @default.
• W2092923321 cites W2008363053 @default.
• W2092923321 cites W2008940139 @default.
• W2092923321 cites W2016086822 @default.
• W2092923321 cites W2019093027 @default.
• W2092923321 cites W2020257412 @default.
• W2092923321 cites W2028666409 @default.
• W2092923321 cites W2029275361 @default.
• W2092923321 cites W2032235066 @default.
• W2092923321 cites W2034820298 @default.
• W2092923321 cites W2036180570 @default.
• W2092923321 cites W2038586807 @default.
• W2092923321 cites W2039049403 @default.
• W2092923321 cites W2040521097 @default.
• W2092923321 cites W2049951334 @default.
• W2092923321 cites W2050596106 @default.
• W2092923321 cites W2071816248 @default.
• W2092923321 cites W2082219113 @default.
• W2092923321 cites W2085397716 @default.
• W2092923321 cites W2086404440 @default.
• W2092923321 cites W2089209309 @default.
• W2092923321 cites W2089483984 @default.
• W2092923321 cites W2095013649 @default.
• W2092923321 cites W2103174300 @default.
• W2092923321 cites W2104485296 @default.
• W2092923321 cites W2117563665 @default.
• W2092923321 cites W2118192897 @default.
• W2092923321 cites W2127048642 @default.
• W2092923321 cites W2139613570 @default.
• W2092923321 cites W2160950237 @default.
• W2092923321 cites W2166291746 @default.
• W2092923321 cites W2180005201 @default.
• W2092923321 cites W2208532882 @default.
• W2092923321 cites W2280729002 @default.
• W2092923321 cites W2283754553 @default.
• W2092923321 cites W2317475893 @default.
• W2092923321 cites W2329648702 @default.
• W2092923321 cites W2403954860 @default.
• W2092923321 cites W2409089508 @default.
• W2092923321 cites W2418978545 @default.
• W2092923321 cites W256420660 @default.
• W2092923321 cites W344470510 @default.
• W2092923321 cites W4240479615 @default.
• W2092923321 cites W4248663651 @default.
• W2092923321 cites W70098085 @default.
• W2092923321 cites W70711085 @default.
• W2092923321 cites W70727130 @default.
• W2092923321 doi "https://doi.org/10.1038/sj.leu.2402199" @default.
• W2092923321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11455967" @default.
• W2092923321 hasPublicationYear "2001" @default.
• W2092923321 type Work @default.
• W2092923321 sameAs 2092923321 @default.
• W2092923321 citedByCount "116" @default.
• W2092923321 countsByYear W20929233212012 @default.
• W2092923321 countsByYear W20929233212013 @default.
• W2092923321 countsByYear W20929233212014 @default.
• W2092923321 countsByYear W20929233212015 @default.
• W2092923321 countsByYear W20929233212016 @default.
• W2092923321 countsByYear W20929233212017 @default.
• W2092923321 countsByYear W20929233212019 @default.
• W2092923321 countsByYear W20929233212020 @default.
• W2092923321 countsByYear W20929233212021 @default.
• W2092923321 countsByYear W20929233212022 @default.
• W2092923321 countsByYear W20929233212023 @default.
• W2092923321 crossrefType "journal-article" @default.
• W2092923321 hasAuthorship W2092923321A5018989541 @default.
• W2092923321 hasAuthorship W2092923321A5020250954 @default.
• W2092923321 hasAuthorship W2092923321A5047214928 @default.
• W2092923321 hasAuthorship W2092923321A5047497411 @default.
• W2092923321 hasAuthorship W2092923321A5052789124 @default.
• W2092923321 hasBestOaLocation W20929233211 @default.
• W2092923321 hasConcept C101544691 @default.

• next